Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • CE Mark Approval Granted For Chembio Diagnostics, Inc. (CEMI) SURE CHECK HIV 1/2 Assay For Rapid Point-of-Care Detection Of HIV 0 comments
    Jun 19, 2013 10:50 AM | about stocks: CEMI

    Point-of-care (POC) diagnostics test leader Chembio Diagnostics announced that European regulators have granted CE Mark approval for the company's SURE CHECK HIV 1/2 Assay. Now cleared for commercialization within the European Union for rapid, point-of-care detection of HIV, the SURE CHECK HIV 1/2 Assay is also FDA approved and is being distributed in the United States by Alere NA as Clearview COMPLETE HIV 1/2.

    Currently, Chembio is working with commercialization partners in Europe and anticipates sales of the SURE CHECK HIV 1/2 Assay in the E.U. by Q1 of 2014. In France alone, the administration of 5.2 million HIV tests (serological) was reported in 2012, and there were more than 28,000 new HIV diagnoses in the EU and European Economic Area (NYSE:EEA) in 2011, according to the European Centre for Disease Prevention and Control and the World Health Organization Regional Office for Europe. As concluded in the 2011 European HIV/AIDS surveillance report published by these groups: "HIV infection is of major public health importance in Europe, with evidence of continuing transmission in specific populations with no clear signs of overall decrease."

    Chembio is focused on developing superior diagnostics to facilitate rapid detection and early treatment of HIV and other infectious diseases. This recently granted CE Mark gives the company an opportunity to bring these key diagnostics to the European market, which is an area that continues to see an increase in HIV among certain significant populations. Chembio will continue working with regulators in Europe to obtain CE Marks for several other diagnostic products this year, as well, including the HIV 1/2 STAT-PAK test, the DPP HIV 1/2 Oral Fluid test and the DPP Syphilis test.

    For more information, visit chembio.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CEMI
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.